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To map presynaptic cholinergic terminal densities in normal aging (n = 36), Alzheimer's disease (AD) (n = 22), and 
Parkinson's disease (PD) (n = 15), we performed single-photon emission computed tomography using [Iz3I] iodoben- 
zovesamicol (IBVM), an in vivo marker of the vesicular acetylcholine transporter. We used coregistered positron emission 
tomography with ["F] fluorodeoxyglucose for metabolic assessment and coregistered magnetic resonance imaging for 
atrophy assessment. In controls (age, 22-91 years), cortical IBVM binding declined only 3.7% per decade. In AD, 
cortical binding correlated inversely with dementia severity. In mild dementia, binding differed according to age of 
onset, but metabolism did not. With an onset age of less than 65 years, binding was reduced severely throughout the 
entire cerebral cortex and hippocampus (about 30%), but with an onset age of 65 years or more, binding reductions 
were restricted to temporal cortex and hippocampus. In PD without dementia, binding was reduced only in parietal 
and occipital cortex, but demented PD subjects had extensive cortical binding decreases similar to early-onset AD. We 
conclude that cholinergic neuron integrity can be monitored in living AD and PD patients, and that it is not so 
devastated in vivo as suggested by postmortem choline acetyltransferase activity (50-80%). 
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Until recently [ 11, noninvasive measure of cholinergic 
terminal loss has not been possible in living human 
brain. Instead, activity decline of choline acetyltransfer- 
ase (ChAT), the enzyme that catalyzes synthesis of ace- 
tylcholine (ACh), has been used extensively as a post- 
mortem marker for the decline of cholinergic neurons, 
notwithstanding that loss of enzyme activity need not 
equate to loss of neurons [2, 31. In demented patients 
with Alzheimer's disease (AD) [4-61 and Parkinson's 
disease (I'D) [7, 81, postmortem studies have demon- 
strated consistently a selective loss of basal forebrain 
cholinergic neurons [9-111 and markedly decreased 
(50-80%) ChAT activity in the associated afferent 
projection areas, ie, cerebral cortex and hippocampus. 
Although cholinergic deficit is unlikely to be the sole 
determinant of cognitive decline in AD or PD, the 
severity of cortical ChAT decline in these disorders has 
been found consistently to be correlated with cognitive 
decline [12-141, while other cortical measures of neu- 
ropeptides and amines and their metabolites have not 
[ 141. The evidence is not clear that cholinergic deficit 
is a significant consequence of normal human aging [ 151. 
To evaluate the distribution of cholinergic neuronal in- 
tegrity within living human brain in normal aging, AD, 
and I'D, we performed single-photon emission computed 
tomography (SPECT) using ['2'I]iodobenz~ve~arnic~l 
( ['*'I] IBVM) [ 161, an analogue of vesamicol that binds 
to the presynaptic vesicular acetylcholine transporter 
(VAChT) [17] and that consequently serves as an in vivo 
marker of presynaptic cholinergic terminal density [ 11. 
These measures were compared then with corresponding 
concomitant measures from positron emission tomogra- 
phy (PET) using ['8F]fluorodeoxyglucose (FDG) for as- 
sessment of cerebral glucose utilization and from mag- 
netic resonance imaging (MRI) for assessment ofatrophy. 
Our scan data indicated that cortical cholinergic termi- 
nals undergo only small age-dependent losses in normal 
aging, are depleted more in mildly demented AD pa- 
tients when disease onset is earlier than age 65 years 
rather than later, and are not so devastated in AD or PD 
as implied by postmortem determinati'ons of ChAT 
activity. 
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Table 1. Characteristics o f  Subject Groupsa 
Group No. Age (yr) Duration (yr) CDR MMSE H&Y 
Alzheimer's disease 
Early onset 13 63 -C 3 6 2 4  
Late onset 9 76 2 5 6 2 2  
Not demented 9 59 2 7 4 2 3  
Demented 6 77 2 5 S t 6  
Parkinson's disease 
1.8 t 0.8 13 2 6 
1.8 2 0.8 12 t 7 
0 ? 00 28 ? 1 2 2 1  
1.1 2 0.7 21 +- 6 3 2 1  
'Characteristics of subject groups. Values are mean t SL). 
CDR = Clinical Dementia Rating [20]; MMSE = Minimental Scale Exam [67]; H&Y = Hoehn and Yahr clinical disability rating [68].  
Subjects and Methods 
Szl bjects 
The total control group for test of age effect was 36 normal 
subjects (1 9 women, 17 men), distributed throughout ages 
ranging from 22 to 91 years. A subgroup of 17 elderly nor- 
mal controls (age, 71 ? 10 years; 7 women, 10 men) was 
used for comparison with the AD and PD groups. Normal 
subjects had no history of significant general medical, neuro- 
logic, or psychiatric illness, head injury with loss of con- 
sciousness, or drug or alcohol dependence, and were taking 
no medications with central nervous system actions. AD and 
PD subjects were taking no medications with actions known 
to affect cerebral metabolism or the central cholinergic sys- 
tem. All clinical diagnoses were made by neurologists. The 
total AD group was 22 subjects, all of whom were required 
to have a clinical diagnosis of probable AD [18] and prior 
FDG-PET evidence of bilateral posterior parietal hypome- 
tabolism typical of AD [19]. One subgroup of 13 patients 
had early-onset disease (at age 64 years or younger); a second 
subgroup of 9 patients had late-onset disease (at age 65 years 
or older). There was a family history clf AD in 61% of the 
early-onset group and in 56% of the late-onset group. These 
AD volunteers were sought out to equalize the range and 
average severity of cognitive impairment within the two sub- 
groups (Table 1). The total P D  group was 15 subjects who 
had a clinical diagnosis of I'D (see Table 1). One subgroup 
of 9 patients was not demented. In a second subgroup of 6 
patients, PD had been present for at least 6 months prior 
to the onset of a complaint of memory loss or intellectual 
decline. Three of these patients had suspected dementia with 
a Clinical Dementia Rating (CDR) [20] score of 0.5; the 
other 3 patients had confirmed progressive dementia (CDR 
= 1, 2, 2). 
Radio tracers 
IBVM was prepared by oxidative radicliodination of the re- 
spective (-)-5-tributyltin precursor, with specific activ- 
ity greater than 1.11 X 10' MBq mmol-' (30,000 Ci/ 
mmol) [16], and was injected intravenously as a 370 MBq 
(10 mCi) dose. To minimize iodine uptake in the thyroid 
gland, each subject was given oral Lugol's solution (one drop 
three times daily) for 1 day prior and for 3 days after the 
study and an oral laxative (Dulcolax R, CIBA, Summit, NJ) 
1 day after the [1z31]IBVM injection, to reduce radiation ex- 
posure to the bowel [ 1 ]. FDG was prepared by direct nucleo- 
philic exchange on a quaternary 4-amirtopyridium resin [2 11 
and was injected intravenously as a 370 MBq (10 mCi) dose. 
The effective dose equivalent for ['231]IBVM was 14.2 mSv 
(1.42 Rem) and for FDG was 10.0 mSv (1.00 Rem). 
Scan Protocols 
In the ['231]IBVM-SPECT protocol for tracer kinetic analy- 
sis, brain ['"II]IBVM images were collected sequentially over 
the first 4.5 hours following injection and for 1 hour on the 
following day [l]. The cerebral tracer input function was 
determined from metabolite-corrected radial arterial blood 
samples. In the simplified scan protocol, three image sets, as 
follows, were obtained in each subject without measuring 
arterial tracer input function: (1) 0 to 30 minutes (for trans- 
port index and anatomy), (2) 3 hours to 3 hours 30 minutes 
(for striatum and cortex anatomy), and (3) 22 hours to 23 
hours (for binding index). Reconstructed spatial resolution 
of the SPECT tomograph (Prism 3000, Picker International, 
Cleveland, OH) was 13.5 mm (full width, half maximum 
[FWHM]) in the center of the transverse plane and axially. 
FDG-PET scans were performed 30 minutes following injec- 
tion. Reconstructed spatial resolution of the PET tomograph 
(Siemens Model 921, CTI Inc, Knoxville, TN)  was 8.4 mm 
(FWHM) in the center of the transverse plane and 7.5 mm 
(FWHM) axially. The MRI scanner (0.5 Tesla, Picker Inter- 
national, Cleveland, OH) was used for proton density images 
(repetition time [TR] 3,000 msec, echo time [TE] 30 msec) 
and T2 images (TR 3,000 msec, T E  100 msec) with 7.0- 
mm-thick axial slices. 
SPECT and PET Image Processing 
Methods for SPECT image processing were described previ- 
ously [I]. In brief, head motion was corrected using fidu- 
cia1 markers in each set of frames. Frames obtained on the 
first and second days were coregistered to the same orienta- 
tion by using a computer algorithm based on image simi- 
larity [22]. An FDG-PET image set corresponding to the 
['231]IBVM-SPECT image set was coregistered in the same 
manner. Image sets were transformed anatomically to the 
standard stereotactic coordinate system [23, 241, and local- 
ized activities were extracted using stereotaxic-based prede- 
fined volumes of interest (VOIs) for subsequent analyses. 
The locations of the predefined VOIs and their atlas- 
indicated [23] Brodmann cortical areas were as follows: fron- 
tal association cortex 6, 8, 9, 10, 11, 44, 45, 46, and 47; 
parietal association cortex 5, 7, 39, and 40; temporal associa- 
tion cortex 21, 22, 37, and 38; occipital cortex 17, 18, and 
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19; primary visual cortex 17; posterior cingulate cortex 23 
and 31; anterior cingulate cortex 24 and 32; and "hippocam- 
pus" (includes parahippocampal, fusiform gyri, and amyg- 
dala complex, as well as the hippocampal formation) 27, 28, 
34, and 35. VOIs for the thalamus, striatum, and cerebellum 
also were predefined. Activities were averaged (area weighted) 
within each VOI. VOI activities were measured separately 
for both hemispheres, but left- and right-sided values were 
averaged together prior to the subsequent analysis. 
In addition, cerebral activity in three dimensions was pro- 
jected to the lateral and medial surface of the brain along 
lines normal to the surface [25], and between-group compar- 
isons using t statistics were performed on a pixel-by-pixel 
basis. T o  demonstrate regional patterns of functional alter- 
ations, two-sample t-statistic values were calculated on a 
pixel-by-pixel basis between normal controls and a group of 
patients, and then transformed to Zvalues by using a proba- 
bility integral transformation. Prior to the analysis, homolo- 
gous pixels in both hemispheres were averaged together, re- 
sulting in symmetrical appearance in superior and inferior 
views. 
Tracer Kinetic Analysis 
Fitted parameters reflecting transport (4) and binding site 
density index (k3) were determined using a three-compart- 
ment model [I]. All subjects had zonal ['2'I]IBVM binding 
indices determined as the ratio of regional activity to cerebel- 
lar activity as measured from the brain image made 22 hours 
after injection. Full tracer kinetic analysis was performed on 
the 36 normal control subjects, 11 AD, and 7 PD subjects 
to assure that the choice of cerebellum as a normalizing refer- 
ence region was proper (ie, no change with age or disease) 
and to demonstrate equivalence of zonal measures based on 
simple normalizing of the delayed activity image and those 
based on more rigorous, but more complicated, kinetic anal- 
ysis. Cerebellar metabolism is nearly normal in AD and P D  
[19, 261, and so, for consistency, corresponding metabolic 
indices were normalized to the cerebellum also and were de- 
termined from FDG scan data in 16 of the 17 elderly normal 
control subjects and in all 22 AD and 15 PD subjects. For 
comparisons, all indices were expressed as percentages of the 
mean normal values from the elderly control group. 
Atrophy Assessment 
To determine the contribution of tissue atrophy to cortical 
binding and metabolic declines, partial volume effects on all 
VOI data were assessed for both [12'II]IBVM and FDG stud- 
ies in 10 of the 17 elderly normal controls, in 15 of the 22 
AD patients (9 early onset, 6 late onset), and in each of the 
I5 PD patients. Proton density and T2-weighted MRI scans 
were registered to the ['231]IBVM-SPECT studies [27]. MRI 
image sets were segmented into brain and nonbrain (cerebro- 
spinal fluid) structures. Brain structures were assigned a value 
of 1 and nonbrain structures a value of 0. The segmented 
MRI data sets were transformed to SPECT orientations by 
using the transformation matrices determined from the origi- 
nal proton density and T 2  data sets. These realigned seg- 
mented MRI data sets were then smoothed with a three- 
PET (8 mm FWHM) image sets. All voxel values in the 
smoothed segmented MRI data then had values ranging from 
0.0 to 1.0. VOIs placed on the SPECT and PET data sets 
were then applied to the smoothed MRI data sets to yield 
a percent-tissue (or tissue fraction) value for each VOI, which 
was applied as an atrophy-partial volume correction term for 
each VOI of each subject. The VOI measures, with and 
without atrophy correction, were compared. 
Statistical Analysis 
Statistical methods included standard correlational analysis 
for determining relationships between different image- 
derived measures (eg, ['231]IBVM binding index versus para- 
metric &), between imaging results and subject age, and be- 
tween imaging results and cognitive measures. A two-factor 
repeated-measures analysis of variance (ANOVA) with gen- 
der and ['231]IBVM binding index as factors and different 
regions as the repeated measure was used to examine gender 
effects in the normal control group. Additional two-factor 
ANOVAs were performed with subject group (diagnosis) and 
imaging measure ( ['231]IBVM binding index or FDG meta- 
bolic index) as factors. An ANOVA was performed to com- 
pare age-matched normal controls and the two AD sub- 
groups (early and late onset), while a separate ANOVA was 
performed to compare controls and the two PD subgroups 
(PD and PD with dementia). For regions showing a signifi- 
cant effect across subject groups, individual t tests were per- 
formed to compare each patient subgroup versus normal 
controls for both ['231]IBVM and FDG measures (Tables 2 
and 3). The reported results do not include corrections for 
multiple comparisons; however, with 10 regions examined 
for two separate patient subgroups and two different imaging 
measures, a conservative multiple comparison adjustment 
would require a significance level of p < 0.001. 
Results 
Normalization 
In normal controls, cerebellar k3 derived from tracer 
kinetic analysis did not  change with aging (n = 36, p 
= 0.28) and  was normal i n  AD (n = 11) and PD ( n  
= 7). Recognizing this measured stability, and previous 
reports of nearly normal cerebellar metabolism in AD 
and PD [ 19, 261, all regional measures were normalized 
to those of the cerebellum, a process that reduced the 
coefficient of variation for k3 in normal cerebral cortex 
from 22 to 16% and that permitted use of relative 22- 
hour  count  distributions as a n  alternative to  the more 
complicated and  time-consuming tracer kinetic analy- 
sis. T h e  correlation was very high ( r  = 0.947), and 
the relationship was very linear between k3 values nor- 
malized t o  cerebellum and  the 22-hour static data, also 
normalized to cerebellum (Fig 1). Regression analysis 
yielded a slope of 1.02 and near-zero intercept of 0.08. 
Near  30% of the variability in the 22-hour data values 
was predicted by differences in k3 (7' = 0.896). Accord- 
ingly, [1231]IBVM binding indices were based subse- 
dimensional Gaussian filter set to match approximately the 
reconstructed resolution of SPECT (15 mm FWHM) and 
quently on the more simple second-day count  distribu- 
tions, rather than on hnetically derived k3 values. 
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Table 2. Indices Measured in Alzbeimer k Diseuse" 
[ 'Z'I]IBVM Binding Index Metabolic Index 
Early Onset Late Onset Early Onset Late Onset 
(n = 113) (n = 9) (n = 13) (n = 9) 
Cerebral cortex 70 t '9" 86 t 18 84 -C 10" 
Frontal 68 i l l b  90 t 21 82 t 14h 
Parietal 59 t 11b 83 i 22 67 t- 12" 
Occipital 65 t 9b 85 -C 17 82 -t I l "  
Primary visual 73 t 12" 93 -C 23 96 t 8 
Postcingulate 68 & 10' 83 t 26 74 i 13' 
Antecingulate 84 t Ibd 90 t 22 95 t 13 
Temporal 58 t 7b 72 +- 16' 79 t I l b  
Hippocampus 70 i 23d 72 t 13" 95 t 11 
Striatum 92 i 20 99 t 22 102 2 8 
Thalamus 77 ? 12d 86 i 19 96 t 10 
'Indices are percentages (mean 5 SD) of mean normal values (n = 17), without atrophy correction. 
Significance of difference from normal (single-tailed unpaired t tests): ' p  < 0.0001; ' p  < 0.001; "p < 0.01. 
IBVM = iodobenzovesamicol. 
Table 3. Indices Measured in Purkinson i Diseasea 
84 i 7b 
85 t 9' 
79 2 9" 
73 t 9" 
82 2 6b 
88 t 9d 
72 i 14" 
88 t 13d 
88 t 15 
93 t 10 
91 t 6 
[ "'IIIBVM Binding Index Metabolic Index 
Nondemented Demented Nondemented Demented 
(n = 9)  (n = 6) (n = 9) (n = 6) 
Cerebral cortex 91 t 18 66 t 13" 93 t 5 d  88 t l l d  
Frontal 95 i 21 67 t 15b 93 t 5 88 t 12" 
ParietaI 81 t 18* 60 2 14' 92 ? 10 81 t 7b 
Occipital 79 2 15d 61 t 12b 91 t 7d 86 ? 7' 
Primary visual 81 -C 19 65 i 16' 90 t Gd 86 t 6' 
Postcingulate 92 It 19 55 2 9" 88 2 9d 77 -+ 13' 
Antecingulate 105 -C 27 78 i 15* 98 i 6 93 t 16 
Hippocampus 86 2 19 68 t 31 89 L 4d 101 t 18 
Striatum 108 5 28 92 t 22 96 +- 5 99 2 8 
Thalamus 95 2 28 84 t 23 93 +- 5 92 t 15 
Temporal 86 t 18 62 +- 13" 95 2 5 94 t 10 
'Indices are percentages (mean ? SD) of inean normal values (n = 17), without atrophy correction. 
Significance of difference from normal (single-tailed unpaired t tests): ' p  < 0.0001; ' p  < 0.001; ' p  < 0.01. 
IBVM = iodobenzovesamicol. 
Normal Controls 
In normal controls (n = 36), across seven decades of age, 
the normalized ['231]IBVM binding index was negatively 
correlated with age at p < 0.05 in all regions, except the 
hippocampus and occipital cortex. In cerebral cortex (Fig 
2),  the decline was approximately 3.7% per decade, with 
no correction for atrophy. The striatum/cerebral cortex ra- 
tio for ['231]IBVM binding index (ri = 36) was 5.17 +- 
0.82 (mean -+ SD). Intersubject coefficients of variation 
(COVs) for ['"I]IBVM binding indilces ranged from 10 to 
30% across regions and were largest in the hippocampus 
(-30%). Variability was nearly identical in young and el- 
derly normals. In 5 tesdretest subjects, intrasubject COV 
measured 5 to 13%, which compares with an intersubject 
COV of -20%. No gender differences were observed in 
the ['231]IBVM binding indices of normals (n = 36). A 
two-factor repeated-measures ANOVA testing gender and 
region showed no gender effect and no gender-by-region 
interactions. 
Alzbeimer j Disease 
In AD patients (n = 22), ['231]IBVM binding of cere- 
bral cortex correlated negatively ( p  = 0.016) with the 
severity of dementia as measured by the CDR [20] (Fig 
3) .  When dementia was mild or moderate, cerebral cor- 
tical binding was more markedly reduced in early-onset 
than in late-onset patients, but binding reductions were 
similar when dementia was severe (see Fig 3 ) .  ANOVA 
indicated significant differences between groups (con- 
trol, early-onset AD, late-onset AD) in all regions ex- 
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Fig 1. The relative cerebral distribution of [I" IJiodobenzo- 
vesamicol (['"IIIBVM) activity ajer 22 hours was equivalent 
to, and could substitute for, the relative binding index k3 
derived from tracer kinetic analysis. Data represent 12 indi- 
vidual brain regions from each o f  54 subjects (36 normal con- 
trols, 11 Alzheimer ? disease, and 7 Parkinson ? disease) and 
are normalized to the cerebellum. 
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Fig 2. Iodobenzovesamicol (pz31JIBVM) binding in cerebral 
cortex declined only approximately 3.7% per decade in nor- 
mal aging (n = 36). No age effect was found in hippocam- 
pal binding. These data are without atrophy correction. B.I. 
= binding index. 
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Severe Mild Moderate 
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Fig 3. In Alzheimer? disease patients (n = 22), p231]iodo- 
benzovesamicol (p231]IBVM) binding (% of mean normal) 
in cerebral cortex correlated negatively (p = 0.016) with the 
severity o f  dementia. When dementia was mild or moderate, 
cerebral cortical binding was more markedly reduced 
in early-onset than in late-onset patients. B. I. = binding 
index; CDR = Clinical Dementia Rating score. 
cept the striatum. When group averages were compared 
for AD (see Table 2; Figs 4 and 5 ) ,  the severity and 
distribution of cerebral hypometabolism was similar in 
early- and late-onset AD subjects, ie, a typical AD pat- 
tern of hypometabolism in association cortex, especially 
parietal, with metabolic sparing of striatum, thalamus, 
pre- and postcentral gyrus, primary visual cortex, and 
hippocampus (medial temporal) cortex [ 191. However, 
the pattern of ['231]IBVM binding differed between 
groups. In early-onset AD, binding was extensively de- 
creased by about 30% throughout the cerebral cortex 
and was especially decreased in temporal cortex (42%). 
In late-onset AD, only temporal cortex binding was 
significantly reduced (28%); hippocampal binding was 
reduced about 30% in both AD groups. 
Parkinson 3 Disease 
ANOVA indicated significant differences between 
groups (control, PD without dementia, PD with de- 
mentia) in all regions except the striatum and the thala- 
mus. In group averages for PD without dementia (see 
Table 3;  Fig G),  metabolism was mildly (10%) reduced 
in occipital, primary visual, and posterior cingulate cor- 
tex and hippocampus. [1231] IBVM binding was reduced 
moderately (20%) in the parietal and occipital cortex, 
but not significantly in the hippocampus. In contrast, 
PD subjects with dementia had more extensive meta- 
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Fig 5. 
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bolic (12-23%) and [1231]IBVM binding reductions 
(33-45%), similar to the severity and neocortical dis- 
tribution of deficits we had found in early-onset AD. 
InJilZlence of  Atrophy 
Cortical atrophy was similar in early- and late-onset 
AD, somewhat less severe in PD with dementia, and 
did not differ from normal controls in PD without 
dementia. For example, the corresponding values for 
['"I] IBVM tissue fraction in temporal cortex (percent- 
age of mean normal) were 86 ? 10, 87 ? 7, 90 ? 9, 
and 99 -t 7, respectively. In most cortical regions, atrophy 
accounted for a very small part of measured binding 
and metabolic reductions (Table 4).  After corrections 
for atrophy, [1231]IBVM binding in early-onset AD sub- 
jects was still decreased by about 20 to 35% in hip- 
pocampus and frontal, temporal, parietal, occipital, 
primary visual, and posterior cingulate cortex; the 
concomitant corrected decreases in glucose metabolic 
rate were about I0 to 25% in frontal, temporal, parietal, 
occipital, and posterior cingulate cortex. Atrophy-cor- 
rected ["31]IBVM binding in demented PD subjects was 
still decreased by about 30 to 40% in frontal, temporal, 
parietal, occipital, primary visual, and posterior cingulate 
cortex; corrected glucose metabolism was reduced by 
about 10 to 20% in parietal, occipital, primary visual, 
and posterior cingulate cortex. 
Discussion 
Validity of  the [i2-'I]IodobenzovesamicoL Method 
After initial demonstrations that vesamicol binding to 
VAChT parallels the normal brain distribution of other 
presynaptic cholinergic markers such as ChAT [28, 
291, lesion experiments [30] and postmortem studies of 
AD cortex [30-321 demonstrated divergence between 
ChAT activity (marked decreases) and vesamicol bind- 
ing (no decreases). These discrepancies have since been 
explained largely as due to the presence of an interfer- 
ing site in the vesamicol binding assay, the vesamicol 
binding protein (VBP), which is not found specifically 
in neurons and which is not related ro the vesamicol 
receptor (VR) [33]. Benzovesamicol and 5-substituted 
benzovesamicols not only have less affinity for VBP 
than vesamicol itself [33], but their affinity for VR, 
based on revised estimates in a more recent report [34], 
is more than 100-fold greater. The affinities of many 
of the benzovesamicols for the VR approach the pico- 
molar range, whereas their affinity for VBP is greater 
than micromolar. This led to our choice of ['231]IBVM 
[I ,  16, 351 for tomographic brain imaging studies 
aimed at in vivo mapping of presynaptic VAChT. 
More recently, the cerebral distribution of VAChT has 
been shown to be identical to ChAT, further support- 
ing its use as a marker for cholinergic neurons [36]. 
The human VAChT cDNA encoding it has been 
cloned and used to localize the VAChT gene, which 
occupies the same chromosome position as the ChAT 
gene [361. 
The in vivo ['231]IBVM method is now validated 
further by our finding cholinergic deficits in the same 
neocortical distributions as have been reported consis- 
tently for postmortem AD and PD brain. These bind- 
ing declines are not regional artifacts caused only by 
neocortical atrophy or by reductions in tracer delivery. 
Our estimates from coregistered MRI scans indicate 
that atrophy can influence the scan measures of disease- 
related binding or metabolic declines reported here, 
but not primarily (see Table 4). This is confirmed fur- 
ther by a lack of concordance found between local 
binding reductions and coexisting atrophy. For exam- 
ple, when early-onset AD patients were compared with 
late-onset patients, neocortical atrophy was similar, but 
cerebral cortical [1231] IBVM binding was markedly dis- 
similar. Furthermore, in demented parkinsonian pa- 
tients compared with late-onset AD patients, neocortex 
had greater [1231]IBVM binding decline in spite of be- 
ing less atrophic. The extraction of ["31]IBVM is low 
(8%) and decreases in local binding measures are not 
in a one-to-one relationship with decreases in local 
delivery, or perfusion. To  the contrary, we found 
greater decreases in ['231]IBVM binding than in corre- 
sponding ["31]IBVM transport and a lack of regional 
Fig 4. Early-onset Alzheimer? disease (AD) (n = 13); summations of ~"I]iodobenzovesamicol (f"I]IBVM) single-photon emission 4 computed tomographic and [18FFIJlorodeo.yglucose (FDG)-positron emission tomographic (PET) scan data shown as Z scores plot- 
ted as three-dimensional stereotactic su face projections. Early IBVM images (at 0-30 minutes) reflected perfision and thus resem- 
bled closely the corresponding FDG metabolic images. Note nearly identical sparing of pre- and postcentral gyrus, prima y visual 
cortex, and hippocampus (medial temporal lobe cortex). Delayed IBVM images (at 22 hours) reflected binding to vesicular acetyl- 
choline transporter and appeared quite different. In early-onset AD, IBVM binding was reduced in the entire cerebral cortex and 
in the hippocampus (medial temporal cortex). LAT = lateral; MED = medial; SUP = superior; INF = inferior. 
Fig 5. Late-onset Alzheimer i disease (AD) (n = 9); summations o f f  231]iodobenzovesamicol (p231]IBVM) single-photon emission 4 computed tomographic and [18F]fluorodeo~glucose (FDG)-positvon emission tomographic (PET) scan data shown as Z scores plot- 
ted as three-dimensional stereotactic su face projections. Although the distribution of FDG deficits (metabolic) in late-onset AD 
closely resembled those in early-onset A D  (see Fig 4), IBVM binding dejcits did not. Binding dejcits involved only the lateral tem- 
poral cortex and hippocampus. LAT = lateral; MED = medial; SUP = superior; INF = inferior. 
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Fig 6. Parkinson i disease (PD); summations o f  ~"I]iodobenzovesamicol (Pz3I]IBVM) single-photon emission computed tomo- 
graphic and ~lnF]~uorodeo~glucose (FDG) positron emission tomographic scan data sbown as Z scores plotted as three-dimensional 
stereotactic surfce projections. (Top) In PD without dementia (n = 9), metabolism was mildly (7-12%) reduced in orbitofion- 
tal, occipital, primary visual, and posterior cingulate cortex and hippocampus. IBVM binding was reduced moderately (20%) in 
the parietal and occipital cortex but not signzjicantly in the hippocampus. (Bottom) In contrast, PD subjects with dementia (n = 
G) had more severe and more extensive cortical hypometabolism and cortical IBVM binding decreases (34%), which were similar 
in severity and distribution to those seen in earh-onset A D  (see Fig 4). LAT = lateral; MED = medial; SUP = superior; INF 
= inferior. 
concordance between perfusion-related and binding- 
related images. Since perfusion and metabolic deficits 
are equivalently coupled in AD [37], FDG (meta- 
bolic), early ['231]IBVM (perfusion), and parametric 
[I2jI] IBVM (transport) images were predictably sim- 
ilar to each other, but were quite different from delayed 
['231]IBVM and parametric ['"IIIBVM k3 images of 
binding (see Fig 4) .  
Normal Aging 
We found only small age-dependent losses of choliner- 
gic terminals in normal aging, a finding compatible 
with most postmortem studies of cholinergic changes 
with aging [ 151. Cholinergic hypotheses of age-related 
memory dysfunction [38] have arisen largely from 
studies of pharmacologically induced cholinergic defi- 
cits and enhancements in aged laboratory animals. 
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Table 4. Injuence of Atrophy on Meamred Reductions of Indicesa 
['231]IBVM Binding Reductions Metabolic Reductions 
Early-Onset AD Demented PD Early-Onset AD Demented PD 
(n = 9) (n = 6 )  (n = 9) (n = 6 )  










32 13 0.41 30 5 0.17 20 16 0.80 14 7 0.50 
41 9 0.22 34 7 0.21 21 1 1  0.52 
42 5 0.12 37 1 0.03 32 7 0.22 20 2 0.10 
35 6 0.17 36 1 0.03 17 8 0.47 15 3 0.20 
22 1 0.05 30 1 0.03 14 1 0.07 
29 9 0.31 41 3 0.07 27 8 0.30 24 4 0.17 
14 9 0.64 
37 0 0.00 
'Total reductions (T) and reductions due to atrophy alone (A) are mean percentages of normal values (n = 10) from data sets made with 
and without atrophy correction. A/T is the fraction of overall measured reduction which is due to atrophy alone. Listed regions differ 
significantly from normal as listed in Tables 2 and 3. 
Postmortem studies of human brain fail to demonstrate 
consistently that cholinergic decline is a consequence 
of normal human aging [15]. Still, one more recent 
report [39] describes marked ChAT decline in the nor- 
mally aging hippocampus after the age of 40 years. Our 
[Iz3I] IBVM scans demonstrate no such age-dependent 
decline in hippocampal cholinergic terminals and only 
a small (3.7%) decline per decade in neocortical cho- 
linergic terminals. 
Alzbeimer 1 Disease 
In AD, our in vivo measures of cholinergic terminal 
deficit generally matched in distribution those reported 
for postmortem measures of ChAT activity decline but 
were less severe. Postmortem ChAT activity is found 
reduced most severely in temporal cortex [40],  is less 
severely reduced in other neocortex and hippocampus 
14-61, but is not reduced in striatum [4, 40, 411, a 
pattern that gave rise to the cholinergic hypothesis that 
attributes this deficit to selective loss of cholinergic 
neurons in the basal forebrain, the source of afferent 
projections to neocortex and hippocampus [9, 11, 421. 
Our binding patterns were similar in more advanced 
AD patients, but in mildly demented patients, binding 
measures differed according to age of onset. 
In mildly demented AD patients, we found wide- 
spread loss of cholinergic terminals in neocortex and 
hippocampus in early-onset disease, but in late-onset 
disease significant reductions were limited to temporal 
cortex and hippocampus. When dementia was severe, 
we found terminal deficits were equally severe and ex- 
tensive in all AD patients (see Fig 3 ) .  This should be 
expected. Neuropathological abnormalities of younger 
AD patients are more severe than those of older AD 
patients [43]. There is postmortem evidence that cho- 
linergic deficits differ in early- and late-onset AD. In 
early-onset AD, severe, widespread ChAT reductions 
have been found in neocortex and hippocampus [44, 
451, but in late-onset AD the ChAT reductions have 
been reported to be limited to temporal cortex [45] 
or to hippocampus [44]. Nucleus basalis degeneration 
might account for this difference; neuronal loss in the 
nucleus basalis is extensive in early-onset AD [46, 471, 
whereas this neuronal population may be near normal 
in late-onset AD [47, 481. Accordingly, the ['231]IBVM 
scans would be demonstrating primarily an innomi- 
natocortical cholinergic system degeneration as the 
early process in early-onset AD, and a septohippocam- 
pal cholinergic system degeneration as the early process 
in late-onset AD. More simply, less cholinergic deficit 
may be needed in older patients to elicit mild symp- 
toms. 
Our local measures of metabolic decline and of cho- 
linergic terminal decline were discordant in AD. This 
is expected because the cortical pattern of metabolic 
change in AD cannot be explained by a more diffuse 
loss of cholinergic afferents. In the resting state, the 
FDG-PET determination of local glucose utilization is 
associated closely with local overall synapse density 
[49]. Because cholinergic terminals represent only 6 to 
7% of total terminals in neocortex [50], a local loss of 
cholinergic neurons/synapses alone has little effect on 
local overall neuron/synapse numbers, and therefore lit- 
tle effect directly on local glucose utilization. Each of 
our AD patients, in both early- and late-onset groups, 
was selected to have an FDG-PET pattern that has 
been reported extensively to be typical of AD [19], 
ie, hypometabolism in cerebral association cortex but 
almost normal metabolism in sensorimotor cortex, pri- 
mary visual cortex, hippocampus, striatum, thalamus, 
pons, and cerebellum. This pattern of metabolic de- 
cline matches closely the postmortem AD distribution 
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of overall neuronal degeneration [51]  and synapse loss 
[52]. In AD striatum, we found cholinergic terminal 
density was normal, like metabolism. Yet, in cerebral 
cortex of mildly demented patients, the extent and se- 
verity of terminal density loss depended on age of onset 
but hypometabolism did not. The primary visual cor- 
tex in AD has no decline in either overall neuron den- 
sity [53], or overall synaptophysin-marked synapse 
density [54], but undergoes a marked loss of ChAT 
activity [54]; correspondingly, in early-onset AD we 
found normal metabolism but decreased cholinergic 
terminal density. In AD hippocampus (ie, medial tem- 
poral cortex), we found decreased cholinergic terminal 
density, which agrees with classic postmortem evidence 
of marked ChAT activity decline, but we found no 
reduction in AD hippocampal metabolism. Our meta- 
bolic findings agree with other reports that PET mea- 
sures of glucose metabolism are normal in AD hippo- 
campus [55-571, even though computed tomographic 
measures of the thickness of the medial temporal lobe 
indicate progressive atrophy in AD [58,  591. This dis- 
crepancy may be explained by the overall rarity of cho- 
linergic synapses in medial temporal cortex. Also, over- 
all synapse density has been reported to be preserved 
in AD hippocampus in spite of coexisting neuron loss 
[52, GO], a process that would tend to preserve metabo- 
lism within a shrunken structure. 
Parkinson j Diseae 
In PD, our in vivo imaging demonstrated that younger 
nondemented patients had mild hypometabolism, 
which was generalized in neocortex, and had mild cho- 
linergic terminal reductions (2O%), which were re- 
stricted to parietal and occipital clortex (see Table 2) .  
We found no evidence of cholinergic deficit in a prefer- 
entially frontal location, which has been implicated as 
a cause of frontal lobe dysfunction in early PD [8, 611. 
In older PD patients who were demented, neocortical 
(especially parietal) cortex was more severely hypometa- 
bolic, consistent with previous reports [26, 621. Cho- 
linergic terminal reductions were more severe and ex- 
tended now throughout the entire neocortex, but 
reductions were inconsistent within the hippocampus 
(see Table 2). These in vivo measures of cholinergic 
terminal decline were less severe, but similarly located, 
compared with postmortem measures reported for 
ChAT in PD. In PD, with or without dementia, stria- 
tal ChAT activity is normal [7, 6311. However, in non- 
demented PD patients, ChAT activity is reduced in 
neocortex and hippocampus [7, 8, 631 and cells are 
lost within the nucleus basalis [64]. In demented PD 
patients, ChAT activity is further reduced 17, 8, 631, 
more so in neocortex than in hippocampus [65].  Our 
scan findings agree with this postmortem evidence, 
which has suggested that a primarily innominatocorti- 
cal cholinergic system degeneration appears early in PD 
and then worsens in older PD patients with the appear- 
ance of dementia. For similar age groups, our scan 
findings in parkinsonian dementia (age, 77 2 5 years) 
form a contrast with those we found in late-onset AD 
(age, 76 ? 5 years), where cholinergic terminal loss 
was focused primarily to hippocampus rather than to 
neocortex (see Table 2). These results are in harmony 
with postmortem evidence that has suggested a primar- 
ily septohippocampal cholinergic system degeneration 
in AD [44, 451. 
Terminal Loss, Enzyme Loss, and Cholinergic 
System Function 
Reductions were consistently less severe for scan- 
determined cholinergic terminal densities than those 
reported in AD and PD for postmortem-determined 
ChAT activities. This discrepancy cannot be explained 
away solely as an artifact of emission tomography con- 
sequent on partial volume effects (661. Instead, our 
data are more likely consistent with a cholinergic de- 
generative process in which enzymatic activity fails 
prior to actual loss of terminals. Our scan measures of 
cholinergic terminal integrity suggest that the choliner- 
gic neuronal system is not so devastated in AD or PD 
as implied by postmortem determinations of ChAT ac- 
tivity, and can be largely intact throughout the cerebral 
cortex in late-onset AD patients when they are only 
mildly demented. These findings conform to a concept, 
usually applied to the basal forebrain cholinergic neu- 
rons [2, 3, 471, that enzymatic dysfunction precedes 
actual neuronal loss in AD. Viewed in perspective, ter- 
minal loss is only one component in a complex mix 
of ongoing degenerative and compensatory processes 
that affect the failing cholinergic system. Measures of 
cholinergic terminal density, or of ChAT activity for 
that matter, are only resting or static properties of the 
cholinergic system, as opposed to more functional or 
dynamic properties, such as rates of ACh synthesis or 
neuronal responsivities to ACh [ 151. Eventually, such 
dynamic measures might provide more direct and satis- 
fying descriptions of cholinergic impairment, but they 
cannot be determined now in living patients. 
Conclusions 
We conclude from our scan data that cortical choliner- 
gic terminals undergo only small age-dependent loss in 
normal aging, are depleted more in mildly demented 
AD patients when disease onset is earlier than age 65 
years rather than later, and are not so devastated in 
AD or PD as implied by postmortem determinations 
of ChAT activity. These results are additional evidence 
that cholinergic neurons in normal aging, AD, and PD 
are not lost to the same extent as are dopaminergic 
neurons in normal aging and PD, and that the survival 
of these neurons can be monitored with noninvasive 
imaging. Further in vivo studies with ['231]IBVM- 
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SPECT should help determine the temporal and spatial 
sequence of declines in cerebral cholinergic terminal 
integrity from the earliest stages of AD and PD. 
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